Study #2023-0202
A Phase 1 multicenter study evaluating the safety and efficacy of ACE1831, an Allogeneic CD20-Conjugated Gamma Delta T-Cell therapy, In adult subjects with relapsed/refractory CD20-expressing B-Cell malignancies
MD Anderson Study Status
Enrolling
Treatment Agent
Cyclophosphamide, Fludarabine, ACE1831, Obinutuzumab
Description
ACE1831 is an off-the-shelf, allogeneic gamma delta T (gdT) cell therapy derived from healthy donors, that is under investigation for the treatment of CD20-expressing B-cell malignancies. The ACE1831-001 study is an open-label, Phase I, first-in-human (FIH) study that aims to evaluate the safety and tolerability, pharmacokinetics and pharmacodynamics, and efficacy of ACE1831 in patients with CD20-expressing Non-Hodgkin lymphoma.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
B-cell Lymphoma, Non Hodgkin Lymphoma, DLBCL, Primary Mediastinal Large B Cell Lymphoma, Marginal Zone Lymphoma, Follicular Lymphoma
Study phase:
Phase I
Physician name:
Ranjit Nair
Department:
Lymphoma/Myeloma
For general questions about clinical trials:
1-844-737-0154
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.